Dr Aldoss on the Use of Revumenib in KMT2A-Rearranged Acute Leukemia

Ibrahim T. Aldoss, MD, discusses the use of revumenib monotherapy in patients with relapsed/refractory acute leukemia harboring KMT2A rearrangements.

Related Keywords

Ibrahimt Aldoss , ,Department Of Hematology Hematopoietic Cell Transplantation ,Division Of Leukemia ,Hematopoietic Cell Transplantation ,Hematologic Oncology ,Onclive Tv ,City Of Hope ,